Novo Nordisk on new key opportunity: We are going into launch mode
The Danish drug group Novo Nordisk expects to launch the new hope of the company’s pipeline in the US by the beginning of 2018. Launches in Japan and Europe will follow later in the year. According to CEO Lars Fruergaard Jørgensen, the weekly GLP-1 analogue provides Novo with a golden opportunity to take on Trulicity, the rival drug from Eli Lilly.
BY MARTIN HAVTORN PETERSEN
Novo Nordisk’s business is under pressure, in the smaller biopharma segment as well as the core business of diabetes treatment. The 2017 Q3 sales dropped in both business segments.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
FDA includes CV benefits of Novo’s Victoza in label
For abonnenter
